Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 26 of 26 entries
Sorted by: Best Match Show Resources per page
Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells.

Oncotarget

Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.
PMID: 30197758
Oncotarget. 2018 Aug 21;9(65):32496-32506. doi: 10.18632/oncotarget.25985. eCollection 2018 Aug 21.

Abelson murine leukemia viral oncogene homolog (ABL) tyrosine kinase inhibitors (TKIs) have been shown to be effective for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia patients. However, resistance to ABL TKIs can develop...

Cite
Okabe S, Tauchi T, Tanaka Y, et al. Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells. Oncotarget. 2018;9(65):32496-32506doi: 10.18632/oncotarget.25985.
Okabe, S., Tauchi, T., Tanaka, Y., & Ohyashiki, K. (2018). Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells. Oncotarget, 9(65), 32496-32506. https://doi.org/10.18632/oncotarget.25985
Okabe, Seiichi, et al. "Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells." Oncotarget vol. 9,65 (2018): 32496-32506. doi: https://doi.org/10.18632/oncotarget.25985
Okabe S, Tauchi T, Tanaka Y, Ohyashiki K. Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells. Oncotarget. 2018 Aug 21;9(65):32496-32506. doi: 10.18632/oncotarget.25985. eCollection 2018 Aug 21. PMID: 30197758; PMCID: PMC6126699.
Copy Download .nbib Format: NLM
Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells.

Oncotarget

Imanishi S, Takahashi R, Katagiri S, Kobayashi C, Umezu T, Ohyashiki K, Ohyashiki JH.
PMID: 29050250
Oncotarget. 2017 Jul 22;8(41):69906-69915. doi: 10.18632/oncotarget.19436. eCollection 2017 Sep 19.

Previous studies showed that downregulation of pyrimidine salvage underlies resistance against 5-azacytidine (AZA), indicating an important role for

Cite
Imanishi S, Takahashi R, Katagiri S, et al. Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells. Oncotarget. 2017;8(41):69906-69915doi: 10.18632/oncotarget.19436.
Imanishi, S., Takahashi, R., Katagiri, S., Kobayashi, C., Umezu, T., Ohyashiki, K., & Ohyashiki, J. H. (2017). Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells. Oncotarget, 8(41), 69906-69915. https://doi.org/10.18632/oncotarget.19436
Imanishi, Satoshi, et al. "Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells." Oncotarget vol. 8,41 (2017): 69906-69915. doi: https://doi.org/10.18632/oncotarget.19436
Imanishi S, Takahashi R, Katagiri S, Kobayashi C, Umezu T, Ohyashiki K, Ohyashiki JH. Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells. Oncotarget. 2017 Jul 22;8(41):69906-69915. doi: 10.18632/oncotarget.19436. eCollection 2017 Sep 19. PMID: 29050250; PMCID: PMC5642525.
Copy Download .nbib Format: NLM
Showing 25 to 26 of 26 entries